Investors

Investors
<picture><source type="image/webp" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/18e05/Image-1.webp 740w,/static/2cf241996b0d6d9b54351b76891640b8/81bef/Image-1.webp 1480w,/static/2cf241996b0d6d9b54351b76891640b8/2d0b8/Image-1.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg" srcSet="/static/2cf241996b0d6d9b54351b76891640b8/bbd3f/Image-1.jpg 740w,/static/2cf241996b0d6d9b54351b76891640b8/087e6/Image-1.jpg 1480w,/static/2cf241996b0d6d9b54351b76891640b8/c9eb6/Image-1.jpg 2960w" alt="&lt;p&gt;Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate Governance
Articles of Association
General meeting
Board of Directors
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Scientific Advisory Board
Archived transactions
Shareholder & stock info
Share monitor
Shareholders
Analyst coverage
Financial reports
Financial calendar
Letter from the CEOOn June 23, 2022, we launched our new company brand, Mendus, emphasizing an even greater focus on changing the course of cancer treatment than ever before in our history. What will really change the course of cancer treatment in the following decades? Mendus will strive to push the boundaries for delaying or preventing tumor recurrence with novel maintenance therapies in AML, ovarian cancer, GIST and over time hopefully in many more forms of cancer. All of this with products that benefit from an excellent safety profile, aiming to minimize damage to health and quality of life.
To read the full letter from the CEO, please click here.
Latest Company PresentationView the latest company presentation
 
Latest press releasesJuly 2022
Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established...
Learn more
June 2022Regulatory Release
Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations. The Company’s stock to continue trading under...
Learn more
Upcoming EventsSeptember 2022
Sachs 22nd Annual Biotech in Europe Forum
The 22nd Annual Biotech in Europe Forum will take place in-person on September 21-22, 2022, at the Mövenpick Hotel in Basel, Switzerland. Mendus' CEO Erik Manting will present on September 21, 2022.
Learn more
September 2022
Pareto Securities’ 13th Annual Healthcare Conference
On 7-8 September 2022, Pareto Securities will host its 13th Annual Healthcare Conference. Mendus' CEO Erik Manting will present at the conference.
Learn more

Contact
Telephone+46 (0)8 732 8400
Emailinfo@mendus.com
<picture><source type="image/webp" srcSet="/static/411b7857055b0888002108e1bcc9e280/e64f1/heado.webp 100w,/static/411b7857055b0888002108e1bcc9e280/8b00d/heado.webp 200w,/static/411b7857055b0888002108e1bcc9e280/9c0a1/heado.webp 400w,/static/411b7857055b0888002108e1bcc9e280/88f3e/heado.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg" srcSet="/static/411b7857055b0888002108e1bcc9e280/93e3f/heado.jpg 100w,/static/411b7857055b0888002108e1bcc9e280/839ae/heado.jpg 200w,/static/411b7857055b0888002108e1bcc9e280/10998/heado.jpg 400w,/static/411b7857055b0888002108e1bcc9e280/a677a/heado.jpg 800w" alt="&lt;p&gt;Image of old buildings by a dock with boats laying in the water in the foreground.&lt;/p&gt;
"/></picture>
Head OfficeVästra Trädgårdsgatan 15

111 53 Stockholm

Sweden
<picture><source type="image/webp" srcSet="/static/99d97027eda87168e92d8d30678ace5b/e64f1/rdo.webp 100w,/static/99d97027eda87168e92d8d30678ace5b/8b00d/rdo.webp 200w,/static/99d97027eda87168e92d8d30678ace5b/9b01d/rdo.webp 400w,/static/99d97027eda87168e92d8d30678ace5b/08dc5/rdo.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg" srcSet="/static/99d97027eda87168e92d8d30678ace5b/93e3f/rdo.jpg 100w,/static/99d97027eda87168e92d8d30678ace5b/839ae/rdo.jpg 200w,/static/99d97027eda87168e92d8d30678ace5b/fa758/rdo.jpg 400w,/static/99d97027eda87168e92d8d30678ace5b/3f065/rdo.jpg 800w" alt="&lt;p&gt;City image from a walkway, with a church and tall buildings in the background.&lt;/p&gt;
"/></picture>
R&D OfficesEmmy Noetherweg 2K 

2333 BK Leiden

The Netherlands
<picture><source type="image/webp" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/e64f1/go.webp 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/8b00d/go.webp 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/9c0a1/go.webp 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/88f3e/go.webp 800w" sizes="(min-width: 400px) 400px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 400px) 400px, 100vw" decoding="async" loading="lazy" src="/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg" srcSet="/static/e29ab9df2993f219c72ad7f14f67fc4a/93e3f/go.jpg 100w,/static/e29ab9df2993f219c72ad7f14f67fc4a/839ae/go.jpg 200w,/static/e29ab9df2993f219c72ad7f14f67fc4a/10998/go.jpg 400w,/static/e29ab9df2993f219c72ad7f14f67fc4a/a677a/go.jpg 800w" alt="&lt;p&gt;Overview image of a city, shot in low sunlight from a far distance.&lt;/p&gt;
"/></picture>
Gothenburg OfficeMendus C/O AstraZeneca BioventureHub

Pepparedsleden 1

431 83 Mölndal

.FullWidthImage-module--bg-image-mobile--1fPGr.FullWidthImage-module--hide-in-mobile--XC8T7.gbi--1479869476-6seVdR9cqsmRrCruwS7MUU:before { opacity: 1; background-image: url('/static/a32348a89302674e113dc101e935b7b3/afb86/about-us-mobile.png'); }

News & eventsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
News & Events

Letter from the CEO

Latest Company Presentation

Latest press releases

Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Upcoming Events

Sachs 22nd Annual Biotech in Europe Forum

Pareto Securities’ 13th Annual Healthcare Conference

Contact

Telephone

Email

Head Office

R&D Offices

Gothenburg Office

News & events

Keep up to date